Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer

Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive... Pharm Res (2018) 35:95 https://doi.org/10.1007/s11095-018-2365-x RESEARCH PAPER Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer 1 2 1 Tanaya Vaidya & Robert M. Straubinger & Sihem Ait-Oudhia Received: 7 September 2017 /Accepted: 10 February 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 ABSTRACT HER2 positive breast cancer cells and deliver chemotherapy, Purpose Trastuzumab combined with Doxorubicin (DOX) and have the potential to improve clinical outcomes. demonstrates significant clinical activity in human epidermal . . growth factor receptor-2 (HER2)-positive breast cancer (BC). KEY WORDS anti-CD3 HER2-positive breast cancer . . However, emergence of treatment resistance and trastuzumab immunoliposomes trastuzumab doxorubicin associated cardiotoxicity remain clinical challenges. In an ef- fort to improve patient outcome, we have developed and eval- uated novel tri-functional immunoliposomes (TFIL) that tar- ABBREVIATIONS get HER2-receptors on BC cells and CD3-receptors on T- BC Breast Cancer lymphocytes, and deliver DOX. CD3 Cluster of Differentiation Receptor Type 3 Methods Trastuzumab (anti-HER2) and OKT-3 (anti-CD3) CTLs Cytotoxic T Lymphocytes antibodies were conjugated to liposomes using a micelle- DOX Doxorubicin transfer method. Cytotoxicity of targeted immunoliposomes HER2 Human Epidermal Growth Factor Receptor Type 2 loaded with DOX was examined in vitro on http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pharmaceutical Research Springer Journals

Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer

Loading next page...
 
/lp/springer_journal/development-and-evaluation-of-tri-functional-immunoliposomes-for-the-jNLWX2Ad0z
Publisher
Springer US
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Biomedicine; Pharmacology/Toxicology; Pharmacy; Biochemistry, general; Medical Law; Biomedical Engineering
ISSN
0724-8741
eISSN
1573-904X
D.O.I.
10.1007/s11095-018-2365-x
Publisher site
See Article on Publisher Site

Abstract

Pharm Res (2018) 35:95 https://doi.org/10.1007/s11095-018-2365-x RESEARCH PAPER Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer 1 2 1 Tanaya Vaidya & Robert M. Straubinger & Sihem Ait-Oudhia Received: 7 September 2017 /Accepted: 10 February 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 ABSTRACT HER2 positive breast cancer cells and deliver chemotherapy, Purpose Trastuzumab combined with Doxorubicin (DOX) and have the potential to improve clinical outcomes. demonstrates significant clinical activity in human epidermal . . growth factor receptor-2 (HER2)-positive breast cancer (BC). KEY WORDS anti-CD3 HER2-positive breast cancer . . However, emergence of treatment resistance and trastuzumab immunoliposomes trastuzumab doxorubicin associated cardiotoxicity remain clinical challenges. In an ef- fort to improve patient outcome, we have developed and eval- uated novel tri-functional immunoliposomes (TFIL) that tar- ABBREVIATIONS get HER2-receptors on BC cells and CD3-receptors on T- BC Breast Cancer lymphocytes, and deliver DOX. CD3 Cluster of Differentiation Receptor Type 3 Methods Trastuzumab (anti-HER2) and OKT-3 (anti-CD3) CTLs Cytotoxic T Lymphocytes antibodies were conjugated to liposomes using a micelle- DOX Doxorubicin transfer method. Cytotoxicity of targeted immunoliposomes HER2 Human Epidermal Growth Factor Receptor Type 2 loaded with DOX was examined in vitro on

Journal

Pharmaceutical ResearchSpringer Journals

Published: Mar 13, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial